Pharmaceutical composition and application thereof

Through the combination of quercetin and nicotine, as a forward allosteric regulator and agonist of α7-nAChR, the problems of limited efficacy and high cost of existing Alzheimer's treatment drugs have been solved, and the efficacy has been significantly improved and The reduction in side effects provides new treatment options for Alzheimer's disease.

CN118903098APending Publication Date: 2024-11-08BEIJING LIFE SCIENCE ACADEMY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410828779.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing Alzheimer's treatment drugs have limited efficacy and are expensive, and lack effective and inexpensive treatment options. Especially, the development of therapeutic drugs based on beta-amyloid and tau has encountered bottlenecks, and α7-nAChR agonists such as Galantamine has side effects and expensive problems.

Method used

A pharmaceutical composition, including quercetin and nicotine, is provided as a combination of a forward allosteric regulator and agonist of α7-nAChR for the prevention and treatment of neurodegenerative diseases by enhancing the activity of α7-nAChR to improve Cognitive function and reduce intracerebral inflammation.

Benefits of technology

This composition significantly improves the efficacy of Alzheimer's treatment, reduces side effects, is relatively cheap, and has a longer acting time as a forward allosteric regulator, providing a new treatment for Alzheimer's disease drug development ideas.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903098A_ABST
    Figure CN118903098A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, in particular to a pharmaceutical composition and application thereof.The pharmaceutical composition comprises quercetin and nicotine, can be applied to preparation of drugs for preventing and / or treating neurodegenerative diseases and is obvious in curative effect. Wherein the quercetin is used as an alpha7-nAChR positive allosteric modulator, the nicotine is used as an alpha7-nAChR agonist, the combined use of the quercetin and the nicotine can significantly improve the treatment effect and reduce the side effect, and a new thought is provided for research and development of drugs for treating the diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a pharmaceutical composition and application thereof. Background Art

[0002] Alzheimer's disease (AD) is one of the major diseases faced by the elderly. The current status of AD is that with the aging of the population, the number of AD patients is increasing year by year; and there is a long time difference between the occurrence of AD pathological changes in neural tissue and the visible clinical cognitive impairment symptoms, resulting in the phenomenon that once the diagnosis is made, the best time for treatment is lost; furthermore, there is currently a lack of effective AD treatment options, and the only remaining treatment options are also very expensive. In this case, the development of low-cost and effective AD treatment drugs has great scientific and application significance.

[0003] Currently, the first-line clinical treatment drugs for AD mainly include cholinesterase inhibitors and NMDA receptor blockers, but their clinical efficacy is limited and they cannot fundamentally delay, block and reverse the pathological process of AD. With the continuous deepening of research on the pathological mechanism of AD, the research and development direction of new anti-AD drugs has gradually shifted to β-amyloid protein and tau protein. However, with the continuous failure of many clinical trials of β-secretase inhibitors, γ-secretase modulators and antibody treatments, the research and development of AD treatment drugs based on this AD pathological mechanism has reached a bottleneck.

[0004] The reduction of cholinergic system function occurs in the early stage of AD and has an important impact on the progression of AD. Neuronal nicotinic acetylcholine receptor (nAChR) in the cholinergic system is a type of non-second messenger-mediated neurotransmitter-bound ion channel in the nervous system. It is involved in the formation of learning and memory, cognitive ability and other regulatory processes in the brain. It also participates in the regulation of many signal transmission processes. Studies have shown that it has significant neuroprotective effects and has potential therapeutic effects on AD. α7-nAChR is an important member of nAChR. It is a non-second messenger-dependent gated ion channel-coupled receptor that can bind to neurotransmitters. At the same time, as an ion channel, it participates in regulating Ca inside and outside the cell. 2+ The flow of plasma is of great significance in the pathogenesis of AD. Studies have shown that the damage of the cholinergic system in AD patients is related to the decrease of α7-nAChR levels, and α7-nAChR plays an important role in counteracting the neurotoxic effects of Aβ.

[0005] Studies have shown that during the aging process, α7-nAChR plays an important role in maintaining synaptic plasticity in the hippocampus. The synaptic function damage and number reduction caused by Aβ oligomer aggregation and its neurotoxic stimulation are closely related to the progression of AD. 2+ With the help of Aβ, it regulates the excitability of the nervous system, the release of multiple neurotransmitters, the induction of LTP, and the improvement of learning and memory functions. Chronic stimulation of Aβ can induce increased expression of α7-nAChR, and at the same time, α7-nAChR expression can increase the passage of Ca 2+ level. Activated α7-nAChR can participate in counteracting the neurotoxicity of Aβ and weaken its induced neuronal apoptosis. There is a high affinity between Aβ and α7-nAChR. This binding forms an Aβ-α7-nAChR complex in nerve cells, which damages α7-nAChR signal transduction, disrupts the transmission of cholinergic neurotransmitters, and causes nerve cell death. Therefore, destroying the binding of Aβ-α7-nAChR is a new therapeutic method for treating functional defects and neurodegeneration caused by Aβ, and α7-nAChR agonists can be used as new drug targets. Studies have shown that the combination of α7-nAChR agonists and their positive allosteric modulators plays an important role in the treatment of AD. The agonist can bind to α7-nAChR, prevent the endocytosis of Aβ and the destruction of synaptic function, and has anti-apoptosis, cognitive function improvement, and anti-protein aggregation effects. Galantamine is a positive allosteric modulator of α7-nAChR, which has been found to enhance and improve the learning and memory functions of AD animal models and is approved for the treatment of mild to moderate Alzheimer's dementia. However, galantamine is very expensive due to its rare extracts and may cause severe skin reactions. It is also contraindicated for patients with epilepsy, hyperkinesia, bronchial asthma, angina pectoris, and bradycardia, so it is not an ideal drug for the treatment of Alzheimer's disease. Summary of the invention

[0006] Therefore, the present invention provides a pharmaceutical composition and its application, which can exert the effects of nicotine and quercetin to prevent and treat neurodegenerative diseases, and has important significance for the research and development of related drugs.

[0007] To this end, the present invention provides the following technical solutions:

[0008] The present invention provides an application of quercetin in the preparation of a positive allosteric modulator, wherein the positive allosteric modulator is an α7-nAChR positive allosteric modulator.

[0009] The invention provides a pharmaceutical composition comprising quercetin and nicotine.

[0010] Optionally, the mass ratio of quercetin to nicotine is 15:1 to 35:1; preferably, the mass ratio of quercetin to nicotine is 30:1.

[0011] The present invention provides a pharmaceutical preparation, comprising the above-mentioned pharmaceutical composition and pharmaceutically acceptable excipients.

[0012] Optionally, the pharmaceutically acceptable excipient is selected from at least one of a pharmaceutically acceptable solvent, a solubilizer, a cosolvent, an emulsifier, an osmotic pressure regulator, a stabilizer, a suspending agent, a coating material, an anti-adhesive, an integrator, a penetration enhancer, a pH regulator, a buffer, a surfactant, an absorbent, a diluent, a filter aid, and a sustained-release material.

[0013] Optionally, the pharmaceutical preparation is selected from an injection or an oral preparation.

[0014] Optionally, the injection is selected from injection solution or powder injection.

[0015] Optionally, the oral preparation is selected from tablets, solutions, capsules, powders, pills, granules, emulsions, syrups, suspensions or oral sustained-release preparations.

[0016] The present invention also provides the use of the above-mentioned pharmaceutical composition or the above-mentioned pharmaceutical preparation in the preparation of medicines for preventing and / or treating neurodegenerative diseases.

[0017] Optionally, the neurodegenerative disease includes schizophrenia, Alzheimer's disease, Parkinson's disease or neuroinflammatory disease.

[0018] The term "α7-nAChR channel" in the present invention refers to the central cation channel formed by the arrangement of α7-nAChR, which is a Ca-permeable 2+ The non-selective cation channel is derived from vertebrates; preferably, the vertebrates include mammals; further preferably, the mammals include horses, cows, mice, rats, dogs, rabbits, chickens, apes, and humans. α7-nAChR can be isolated from tissue probes of the vertebrate organisms, or produced by a method of recombinant biomaterials capable of expressing α7-nAChR protein.

[0019] α7-nAChR channel activity can be measured by, for example, patch clamp techniques, whole-cell current, radioligand binding experiments, or fluorescence (calcium ion sensitive dye) detection methods. Nicotine can trigger calcium ion influx by stimulating α7-nAChR. When nicotine binds to the outer binding site of the nicotinic receptor, α7-nAChR undergoes a conformational change, causing the channel to open, which allows extracellular calcium ions to enter the cell. Therefore, the effect of a compound on α7-nAChR can be evaluated by detecting the intracellular calcium ion concentration. Typically, the α7-nAChR channel activity assay comprises the following steps: (1) contacting quercetin with fluorescent cells expressing α7-nAChR, and before, simultaneously with, or after contact, using nicotine to stimulate α7-nAChR to produce Ca 2+ (2) Detect changes in α7-nAChR channel activity to reflect the enhancing effect of quercetin on nicotine-activated α7-nAChR.

[0020] The technical solution of the present invention has the following advantages:

[0021] 1. The present invention provides an application of quercetin in the preparation of a positive allosteric modulator, wherein the positive allosteric modulator is an α7-nAChR positive allosteric modulator. Quercetin is used as an effective ingredient of the α7-nAChR positive allosteric modulator, and it is proposed that quercetin can be used as an α7-nAChR positive allosteric modulator, which has a relatively low price and few side effects.

[0022] 2. The present invention also provides the use of the above-mentioned pharmaceutical composition including quercetin and nicotine or the above-mentioned pharmaceutical preparation in the preparation of medicines for preventing and / or treating neurodegenerative diseases, and the therapeutic effect is obvious. Among them, quercetin is used as a positive allosteric modulator of α7-nAChR, and nicotine is used as an α7-nAChR agonist. Compared with the α7-nAChR agonist nicotine, the α7-nAChR positive allosteric modulator quercetin is less likely to produce receptor inactivation phenomenon and has a longer action time. The α7-nAChR positive allosteric modulator quercetin can be combined with the allosteric regulation site of the transmembrane domain of the receptor, and by increasing the intracellular calcium ion influx, it further enhances the activation effect of the agonist nicotine on α7-nAChR, which plays an important role in improving brain cognition and reducing brain inflammation. Therefore, the combined use of α7-nAChR agonist nicotine and the positive allosteric modulator quercetin can significantly improve the therapeutic effect and reduce side effects, providing a new idea for the development of drugs for treating the above-mentioned diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0024] Figure 1 In Experimental Example 1 of the present invention, different doses of α7-nAChR positive allosteric modulators induce Ca 2+ Image of fluorescence intensity changes over time;

[0025] Figure 2 This is an image of the change in the time it takes for each group of mice to enter a hole in each test in Experimental Example 2 of the present invention;

[0026] Figure 3 This is a statistical image of the hole entry time of mice in each group after two trainings in the Barnes maze experiment in Experimental Example 2 of the present invention;

[0027] Figure 4 This is the cognitive index image of each group of mice in the novel object recognition experiment in Experimental Example 2 of the present invention. DETAILED DESCRIPTION

[0028] Experimental Example 1

[0029] Intracellular calcium detection assay to evaluate the potentiation of nicotine as an α7-nAChR agonist by quercetin

[0030] (1) First, HEK293T cells (Wuhan Pronocell Life Science Co., Ltd.) were cultured at 15 × 10 5The cells were inoculated into a 6-well plate at a density of 1 mL / well of DMEM + 10% FBS (fetal bovine serum) for 24 hours, and then 20 μL of pSLentiEF1-CHRNA7 lentivirus containing α7-nAChR (manufacturer: Heyuan Bio) was added to each well. The plate was placed in a 37°C, 5% CO2 constant temperature incubator for overnight culture. After 12 hours of adding the virus, the original culture medium was discarded, and 1 mL / well of fresh complete culture medium (DMEM + 10% FBS (fetal bovine serum)) was added to continue the culture. After 48 hours of adding the virus, 1 mL / well of 5 μg / mL puromycin was added for drug screening, and the complete culture medium containing 1 mL / well of 5 μg / mL puromycin was replaced every 2 to 3 days. After the cells grew to 80% confluence, the cells were digested and inoculated into a 25 cm × 25 cm cell culture flask for continued culture. Finally, the cell lines with stably transfected mixed clones were obtained by continuous passage for 2 to 3 times. The cells were observed under a fluorescence microscope, and the obtained cells carried the mCherry (red fluorescent protein) label, proving that the lentiviral infection was successful and the obtained cells were cells that stably expressed α7-nAChR.

[0031] (2) The cells stably expressing α7-nAChR obtained in step (1) were made into 15×10 4 The cell suspension of cells / mL was added to a black-bottomed 96-well plate at a volume of 100 μL per well and cultured in an incubator for 24 h before being used for subsequent experiments.

[0032] (3) Observe the cells and confirm that the cells are in good condition. Then dilute the R8191 Calcium 6 Assay Kit dye (commercial calcium ion dye) with HBSS buffer solution (pH = 7.4) at a volume ratio of 1:10 to prepare a Ca 2+ Dye working solution. Add 100 μL of the above Ca2+ to each well. 2+ Dye working solution, load the dye, and then place it in a 37°C, 5% CO2 constant temperature incubator and incubate for 2 hours in the dark.

[0033] (4) preparing the α7-nAChR agonist, the α7-nAChR positive allosteric modulator, and the control group α7-nAChR positive allosteric modulator as follows:

[0034] Preparation of α7-nAChR agonist (nicotine): weigh an appropriate amount of nicotine and dissolve it in DMSO to obtain a nicotine stock solution with a concentration of 10 mM;

[0035] Preparation of α7-nAChR positive allosteric modulator (quercetin): weigh an appropriate amount of quercetin and dissolve it in DMSO to obtain a quercetin stock solution with a concentration of 10 mM;

[0036] Preparation of the α7-nAChR positive allosteric modulator [PNU-120596 (N-(5-chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)urea)] in the control group: weigh an appropriate amount of PNU-120596 and dissolve it in DMSO to obtain a PNU-120596 stock solution with a concentration of 10 mM.

[0037] (5) Drug addition: The cells loaded with dye in (3) were divided into 6 groups. Six wells in a 96-well plate were randomly selected from each group and named as 10 μM quercetin group, 50 μM quercetin group, 100 μM quercetin group, 200 μM quercetin group, 500 μM quercetin group, and 20 μM PNU-120596 group, respectively.

[0038] To the 10 μM quercetin group, the α7-nAChR positive allosteric modulator (quercetin) prepared in step (4) was first added, and then the α7-nAChR agonist (nicotine) prepared in step (4) was added, and then HBSS buffer (Hanks balanced salt solution) was gradually added to make the final concentration of nicotine 10 μM and the final concentration of quercetin 10 μM.

[0039] The only difference between the 50 μM quercetin group, the 100 μM quercetin group, the 200 μM quercetin group, the 500 μM quercetin group and the 10 μM quercetin group was that the final concentrations of quercetin were 50 μM, 100 μM, 200 μM and 500 μM, respectively.

[0040] The control group α7-nAChR positive allosteric modulator (PNU-120596) prepared in step (4) was first added to the 20 μM PNU-120596 group, followed by the α7-nAChR agonist (nicotine) prepared in step (4), and then HBSS buffer (Hanks balanced salt solution) was gradually added to make the final concentration of nicotine 10 μM and the final concentration of PNU-120596 20 μM.

[0041] (6) After drug addition, intracellular calcium concentration was measured using a fluorescence imaging plate reader (Flexstation, Molecular Devices, Sunnyvale, CA, USA). The emission cutoff wavelength was set to 515 nm, the excitation wavelength was set to 485 nm, the emission wavelength was set to 525 nm, and the reading interval was set to 1.6 s. The relative fluorescence intensity value (Relative Fluorescence Unit, RFU) was calculated to reflect the change in intracellular calcium concentration. At least 5 cells were selected as the detection points for the relative fluorescence intensity.

[0042] get Figure 1Different doses of α7-nAChR positive allosteric modulators induced intracellular Ca 2+ The graph of fluorescence intensity changing with time, where the horizontal axis is time and the vertical axis is the relative fluorescence intensity value. Figure 1 It can be seen that the intracellular Ca 2+ The fluorescence intensity reached a peak, and the peak time was almost the same. 100μM quercetin can significantly enhance the calcium influx induced by 10μM nicotine. Different doses of quercetin caused intracellular Ca 2+ The changes of fluorescence intensity over time are obviously different, and the increase of quercetin concentration from 10 μM to 500 μM can dose-dependently enhance the calcium influx of α7-293T cells induced by nicotine. This shows that quercetin is a positive allosteric modulator of α7-nAChR. The α7-nAChR positive allosteric modulator PNU-120596 (PNU) was selected as a positive control, and 20 μM PNU enhanced the increase of calcium ions induced by nicotine. Although the amount of quercetin used in the present invention is relatively large, it can fully achieve the effect that PNU can achieve, and can be used as a positive allosteric modulator of α7-nAChR.

[0043] Experimental Example 2

[0044] The effects of nicotine and quercetin combination on Alzheimer's disease mice (APP / PS1) were tested.

[0045] 1. Mouse selection, grouping, and drug administration

[0046] APPswe / PS1dE9 (APP / PS1) double transgenic mice were selected as an animal model of Alzheimer's disease. At 1 to 3.5 months of age, 25% of the mice experienced at least one epilepsy, and the mouse tails may appear bent due to background influences; at 4 to 5 months of age, the incidence of epilepsy increased to 55%, and there was a 10-15% mortality rate; at 6 months of age, a small amount of deposits were found in the hippocampus; at 7 months of age, coordination was impaired; at 9 months of age, abundant plaques appeared in the hippocampus and cortex; at 12 months of age, the plaques tended to be saturated; at 13 months of age, more errors were made in the water maze than normal mice; at 14 months of age, the body weight was lower than that of normal mice, and the sense of balance on the rotating rod was reduced.

[0047] Randomization

[0048] (1) Nicotine group (APP-NIC or APP / PS1-NIC): 10 APP / PS1 mice;

[0049] (2) quercetin group (APP-QU or APP / PS1-QU): 10 APP / PS1 mice;

[0050] (3) Nicotine + quercetin group (APP-NIC + QU or APP / PS1-NIC + QU): 10 APP / PS1 mice;

[0051] (4) saline group (APP-NS or APP / PS1-NS): 10 APP / PS1 mice;

[0052] (5) APP / PS1 negative control group (C57-NS): 7 APP / PS1 negative mice from the same litter.

[0053] The drug administration conditions are shown in Table 1.

[0054] The nicotine salt solution used was a physiological saline solution of di-L-(+)-nicotine tartrate dihydrate (in which nicotine accounted for about one-third by mass); the quercetin solution used was an aqueous solution of quercetin, in which DMSO was used as a solubilizing agent, and the DMSO concentration was 0.2%; when the APP-NIC+QU group was administered, the nicotine salt solution and the quercetin solution were injected separately.

[0055] Table 1

[0056]

[0057] 2. Barnes maze test

[0058] Barnes maze test method:

[0059] (1) Place the mouse in the target box through the target hole and allow it to adapt for 30 seconds.

[0060] (2) The mice were then placed in a plastic cylinder in the center of the maze to restrict their movement for 5 seconds.

[0061] (3) During the first training session, after the mouse successfully escaped and entered the target box, it was allowed to stay in the target box for 30 s;

[0062] Alternatively, if the mouse could not find the target box within 4 min, it was moved from the maze to the target box and remained there for 30 s.

[0063] During the second and third training sessions, after the mouse successfully escaped and entered the target box, it was allowed to stay in the target box for 30 s;

[0064] Alternatively, if the mouse could not find the target box within 6 min, it was moved from the maze to the target box and remained there for 30 s.

[0065] (4) Clean the maze with 70% alcohol and randomly rotate the positions of the holes in the maze (the target hole is always fixed in the same direction).

[0066] (5) The next mouse is trained until all mice are trained.

[0067] The training was conducted once a day, starting at 9 am every day until all mice were trained. All mice were given medication after training every day. To avoid more negative effects on the mice, the maximum duration of each training was unified. If the mice did not enter the hole during this time, it was recorded as the maximum duration. The time it took for each mouse to enter the target hole from the starting point (i.e., the center of the maze) was recorded, and the data was processed to obtain Figure 2 , 3 . Figure 2 The figure shows the change in the time each group of mice spends in the hole in each test. The horizontal axis is the number of tests and the vertical axis is the time. Figure 3 The following is the statistics of the time each group of mice spent in the hole after two trainings. The horizontal axis is the group and the vertical axis is the time. Figure 2 It can be seen that with the increase in the number of training times, the time it took for mice in the four groups of APP-NIC, APP-QU, APP-NIC+QU, and C57-NS to find the target hole and enter it gradually decreased. Among them, the APP-NIC+QU group had the shortest time and the most obvious effect due to the combined administration of nicotine and quercetin; the APP-NS (normal saline group) had relatively poor memory, and the time it took to enter the safety hole in the third training was even longer than the second.

[0068] from Figure 3 It can be seen that the time it takes for mice in the APP-NIC+QU group to enter the target hole is significantly different from that in the APP-NS group. In terms of specific data, the average time it takes for mice in the APP-NIC, APP-QU, APP-NIC+QU, APP-NS, and C57-NS groups to enter the hole after two training sessions is 60.7s, 85.3s, 23.2s, 150.6s, and 68.8s, respectively. It can also be seen that the mice in the APP-NIC+QU group took the shortest time, which is more than half shorter than the APP-NIC group with the second shortest time. Even the APP-NIC group with the second shortest time took less time than the negative control group C57-NS. This shows that nicotine improves the spatial memory ability of mice, and this effect is greatly enhanced after combined administration of quercetin.

[0069] 3. Novel Object Recognition

[0070] The steps of the novel object recognition experiment (NOR) are as follows:

[0071] (1) Three days before training and testing, stroke the mice for 1 min every day to avoid stimulating them and help them eliminate the unfamiliarity with the tester.

[0072] (2) 24 h before the test, place the mice in the test room to acclimate to the test environment.

[0073] (3) 24 h before testing, mice were familiarized with the open field for 4 min.

[0074] (4) Start training for 4 minutes. First, place two objects A and B on the left and right ends of one side wall. Place the mouse in the arena with its back facing the two objects, and keep the tip of the mouse's nose at the same distance from the two objects. After the mouse is placed in the arena, turn on the video recording device to record the mouse's contact with the two objects, including the number of times the nose or mouth touches the objects and the time spent exploring within 2 to 3 cm of the objects (putting the front paws on the object, sniffing the object, licking the object, etc. are all considered exploration of the object. Posing or climbing on the object without moving does not count as exploration of the new object).

[0075] (5) After the test, the mice were immediately placed back into the original mouse box and allowed to rest for 1 hour (during this period, the mice remained in the test room).

[0076] (6) After the mice have rested, the test is started. At this time, object B in the arena is replaced with object C. The mice are still facing away from the two objects, with their noses at the same distance from the two objects. The observation time is 5 minutes. The video is also recorded with the same observation indicators as in step (4). The main observation is the exploration of object C by the mice.

[0077] (7) After all experiments are completed, return the mice to their original breeding room.

[0078] The purpose of the experiment is to detect the cognitive status of mice by the number, time and distance of their exploration of new and old objects, that is, the number, time and distance of their activities around new and old objects: if the mice have poor cognitive ability, there will be no difference in the exploration of new and old objects; if the mice have normal cognitive ability, they will explore new things longer than old things. The recognition index (RI) calculation formula is: RI = time around new object (C) / (time around new object (C) + time around old object (A)) × 100%.

[0079] Three weeks after administration, mice in each group were subjected to a novel object recognition test. Figure 4 As shown, the horizontal axis is the group and the vertical axis is the cognitive index. In terms of specific data, the average values ​​of the cognitive index of mice in the APP-NIC, APP-QU, APP-NIC+QU, APP-NS, and C57-NS groups were 50%, 53%, 63%, 52%, and 59%, respectively. The cognitive index of mice in the APP-NIC+QU group was significantly higher than that in other groups. At the same time, the cognitive index of the APP-NIC and APP-QU groups was equivalent to that of the APP-NS group, which shows that nicotine or quercetin alone does not play an effective role in improving the cognitive memory of mice, while the combined administration of nicotine and quercetin can improve the cognitive memory ability of mice.

[0080] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. A use of quercetin in the preparation of a positive allosteric modulator, characterized in that: The positive allosteric modulator is an α7-nAChR positive allosteric modulator.

2. A pharmaceutical composition, characterized in that Includes quercetin and nicotine.

3. The pharmaceutical composition according to claim 2, characterized in that The mass ratio of quercetin to nicotine is 15:1 to 35:1; preferably, the mass ratio of quercetin to nicotine is 30:

1.

4. A pharmaceutical preparation, characterized in that The pharmaceutical composition according to claim 2 or 3 also includes a pharmaceutically acceptable excipient.

5. The pharmaceutical preparation according to claim 4, characterized in that The pharmaceutically acceptable excipient is selected from at least one of pharmaceutically acceptable solvents, solubilizers, cosolvents, emulsifiers, osmotic pressure regulators, stabilizers, suspending agents, coating materials, anti-adhesives, integrators, penetration enhancers, pH regulators, buffers, surfactants, absorbents, diluents, filter aids, and sustained-release materials.

6. The pharmaceutical preparation according to claim 4 or 5, characterized in that The pharmaceutical preparation is selected from an injection or an oral preparation.

7. The pharmaceutical preparation according to claim 6, characterized in that The injection is selected from injection solution or powder injection.

8. The pharmaceutical preparation according to claim 6, characterized in that The oral preparation is selected from tablets, solutions, capsules, powders, pills, granules, emulsions, syrups, suspensions or oral sustained-release preparations.

9. Use of the pharmaceutical composition according to claim 2 or 3 or the pharmaceutical preparation according to any one of claims 4 to 8 in the preparation of a medicament for preventing and / or treating a neurodegenerative disease.

10. The use according to claim 9, characterized in that: The neurodegenerative diseases include schizophrenia, Alzheimer's disease, Parkinson's disease or neuroinflammatory diseases.